Keep up with the latest headlines in dermatology from the past week, including Novan, Inc.'s bankruptcy filing, rates of melanoma in European Union countries, and more.
Earlier this week, pharmaceutical company Novan, Inc., filed for bankruptcy. The Durham, North Carolina,- based company entered into a stalking horse asset purchase agreement with Ligand Pharmaceuticals prior to filing for Chapter 11. Novan, Inc., currently has 3 drugs in its pipeline, including berdamizer gel 10.3% (SB206) for the treatment of molluscum contagiosum, which has a US FDA PDUFA goal date of January 5, 2024. The company reports that it plans to work with the FDA toward this approval, despite the filing.
A new study from Northwestern Medicine reports that despite the prevalence of use of skin lightening products in the US, particularly among women with skin of color, users do not typically know the risks that accompany the products.
“The most surprising finding was the lack of awareness of ingredients in products being purchased over the counter and their potential detrimental effects,” said lead investigator Roopal Kundu, MD.
In the European Union, melanoma is ranked as the 6th most common form of cancer among both men and women. Despite this, Euronews reports the rise of anti-sunscreen "influencers" on social media. Among men, the Netherlands has the highest melanoma incidence in Europe, with Denmark ranking first in cases of melanoma per 100,000 women. Denmark is also the country leading in melanoma deaths of women, while Slovakia leads in deaths of men per 100,000 people.
The Melanoma Research Alliance (MRA) has announced its 4 2023 Dermatology Fellowship Award Recipients. Recipients include Pietro Berico, PhD, New York University Grossman School of Medicine; Neil Neumann MD, PhD, The Rockefeller University; Simon F. Roy MD, Yale University; and Xiao Zhang PhD, The University of California, Los Angeles.
Israeli dermatology specialist Alina Luzinski, MD, spoke with The Jerusalem Post about the etiology of psoriasis. She also delved into her recommended best practices for treating psoriasis in a new patient, as well as providing an overview of psoriatic treatment options and the psychosocial impacts of the condition.
Rinky Kapoor, MD, discussed psychodermatology with The Indian Express, explaining the connections between the mind and skin.
"It involves the evaluation of how certain skin disorders are connected to the psyche," she said.
Allied Market Research reported that by 2032, the teledermatology market is expected to reach $38.9 billion. In 2022, the market stood at an estimated value of $9.5 billion.
"The global teledermatology market is driven by several factors, such as a rise in the prevalence of skin disorders such as acne, atrophic dermatitis, rosacea, skin cancer, and various others, technological advancements in telehealth services, a rise in the number of teledermatology service providers," according to GlobeNewswire.